nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS1—esophageal cancer	0.456	0.636	CbGaD
Bismuth Subsalicylate—PTGS2—esophageal cancer	0.261	0.364	CbGaD
Bismuth Subsalicylate—PTGS2—Cisplatin—esophageal cancer	0.0677	0.709	CbGbCtD
Bismuth Subsalicylate—ALB—Methotrexate—esophageal cancer	0.0277	0.29	CbGbCtD
Bismuth Subsalicylate—Venous thrombosis—Carboplatin—esophageal cancer	0.00746	0.0956	CcSEcCtD
Bismuth Subsalicylate—Fluid overload—Carboplatin—esophageal cancer	0.00647	0.083	CcSEcCtD
Bismuth Subsalicylate—TF—exocrine gland—esophageal cancer	0.00613	0.246	CbGeAlD
Bismuth Subsalicylate—Extravasation—Carboplatin—esophageal cancer	0.00461	0.0591	CcSEcCtD
Bismuth Subsalicylate—Haemolysis—Cisplatin—esophageal cancer	0.00371	0.0476	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Carboplatin—esophageal cancer	0.00339	0.0435	CcSEcCtD
Bismuth Subsalicylate—Localized exfoliation—Capecitabine—esophageal cancer	0.00323	0.0414	CcSEcCtD
Bismuth Subsalicylate—TF—epithelium—esophageal cancer	0.00267	0.107	CbGeAlD
Bismuth Subsalicylate—TF—bronchus—esophageal cancer	0.00263	0.106	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Cisplatin—esophageal cancer	0.00219	0.028	CcSEcCtD
Bismuth Subsalicylate—TF—digestive system—esophageal cancer	0.00203	0.0815	CbGeAlD
Bismuth Subsalicylate—Fluid overload—Cisplatin—esophageal cancer	0.0019	0.0243	CcSEcCtD
Bismuth Subsalicylate—TF—lung—esophageal cancer	0.0017	0.0681	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Capecitabine—esophageal cancer	0.00161	0.0207	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Capecitabine—esophageal cancer	0.0015	0.0192	CcSEcCtD
Bismuth Subsalicylate—Infection—Carboplatin—esophageal cancer	0.00143	0.0183	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Cisplatin—esophageal cancer	0.00135	0.0173	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Cisplatin—esophageal cancer	0.00124	0.0159	CcSEcCtD
Bismuth Subsalicylate—Pain—Carboplatin—esophageal cancer	0.00123	0.0157	CcSEcCtD
Bismuth Subsalicylate—TF—lymph node—esophageal cancer	0.00116	0.0466	CbGeAlD
Bismuth Subsalicylate—Body temperature increased—Carboplatin—esophageal cancer	0.00114	0.0146	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Cisplatin—esophageal cancer	0.00113	0.0145	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Cisplatin—esophageal cancer	0.000995	0.0128	CcSEcCtD
Bismuth Subsalicylate—Deafness—Cisplatin—esophageal cancer	0.000958	0.0123	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Methotrexate—esophageal cancer	0.000933	0.012	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Methotrexate—esophageal cancer	0.000916	0.0117	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Capecitabine—esophageal cancer	0.000914	0.0117	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Cisplatin—esophageal cancer	0.000861	0.011	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Capecitabine—esophageal cancer	0.000831	0.0107	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Capecitabine—esophageal cancer	0.000795	0.0102	CcSEcCtD
Bismuth Subsalicylate—PTGS1—epithelium—esophageal cancer	0.000791	0.0318	CbGeAlD
Bismuth Subsalicylate—Ecchymosis—Capecitabine—esophageal cancer	0.000787	0.0101	CcSEcCtD
Bismuth Subsalicylate—PTGS1—smooth muscle tissue—esophageal cancer	0.000762	0.0306	CbGeAlD
Bismuth Subsalicylate—PTGS2—epithelium—esophageal cancer	0.000756	0.0304	CbGeAlD
Bismuth Subsalicylate—PTGS2—bronchus—esophageal cancer	0.000745	0.0299	CbGeAlD
Bismuth Subsalicylate—Extravasation—Methotrexate—esophageal cancer	0.000743	0.00952	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Capecitabine—esophageal cancer	0.000733	0.0094	CcSEcCtD
Bismuth Subsalicylate—PTGS2—smooth muscle tissue—esophageal cancer	0.000729	0.0293	CbGeAlD
Bismuth Subsalicylate—Abdominal discomfort—Cisplatin—esophageal cancer	0.00071	0.0091	CcSEcCtD
Bismuth Subsalicylate—Deafness—Capecitabine—esophageal cancer	0.000706	0.00905	CcSEcCtD
Bismuth Subsalicylate—PTGS1—trachea—esophageal cancer	0.0007	0.0281	CbGeAlD
Bismuth Subsalicylate—PTGS2—trachea—esophageal cancer	0.000669	0.0269	CbGeAlD
Bismuth Subsalicylate—Lethargy—Capecitabine—esophageal cancer	0.000645	0.00827	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Capecitabine—esophageal cancer	0.000634	0.00813	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—esophageal cancer	0.000619	0.00793	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—esophageal cancer	0.000603	0.0242	CbGeAlD
Bismuth Subsalicylate—PTGS1—digestive system—esophageal cancer	0.000602	0.0242	CbGeAlD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—esophageal cancer	0.000586	0.00751	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Capecitabine—esophageal cancer	0.000577	0.0074	CcSEcCtD
Bismuth Subsalicylate—PTGS2—digestive system—esophageal cancer	0.000575	0.0231	CbGeAlD
Bismuth Subsalicylate—Tinnitus—Cisplatin—esophageal cancer	0.000553	0.00709	CcSEcCtD
Bismuth Subsalicylate—Asthma—Capecitabine—esophageal cancer	0.000546	0.007	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Capecitabine—esophageal cancer	0.000524	0.00671	CcSEcCtD
Bismuth Subsalicylate—Erythema—Cisplatin—esophageal cancer	0.000516	0.00662	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lung—esophageal cancer	0.000503	0.0202	CbGeAlD
Bismuth Subsalicylate—Weight increased—Capecitabine—esophageal cancer	0.000497	0.00637	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lung—esophageal cancer	0.000481	0.0193	CbGeAlD
Bismuth Subsalicylate—Lethargy—Methotrexate—esophageal cancer	0.00048	0.00615	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Capecitabine—esophageal cancer	0.000459	0.00589	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Capecitabine—esophageal cancer	0.000437	0.0056	CcSEcCtD
Bismuth Subsalicylate—Oedema—Cisplatin—esophageal cancer	0.000421	0.0054	CcSEcCtD
Bismuth Subsalicylate—Infection—Cisplatin—esophageal cancer	0.000419	0.00537	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Capecitabine—esophageal cancer	0.000413	0.0053	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Capecitabine—esophageal cancer	0.000408	0.00522	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—esophageal cancer	0.000407	0.00521	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Cisplatin—esophageal cancer	0.000402	0.00515	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—esophageal cancer	0.00039	0.005	CcSEcCtD
Bismuth Subsalicylate—Erythema—Capecitabine—esophageal cancer	0.000381	0.00488	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Capecitabine—esophageal cancer	0.000373	0.00478	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Cisplatin—esophageal cancer	0.000366	0.00469	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Methotrexate—esophageal cancer	0.000363	0.00465	CcSEcCtD
Bismuth Subsalicylate—Pain—Cisplatin—esophageal cancer	0.00036	0.00462	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Cisplatin—esophageal cancer	0.000347	0.00445	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—esophageal cancer	0.000344	0.0138	CbGeAlD
Bismuth Subsalicylate—Epistaxis—Methotrexate—esophageal cancer	0.000342	0.00438	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Cisplatin—esophageal cancer	0.000333	0.00427	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—esophageal cancer	0.000329	0.0132	CbGeAlD
Bismuth Subsalicylate—Hepatitis—Methotrexate—esophageal cancer	0.000325	0.00417	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Capecitabine—esophageal cancer	0.000313	0.00401	CcSEcCtD
Bismuth Subsalicylate—Oedema—Capecitabine—esophageal cancer	0.000311	0.00398	CcSEcCtD
Bismuth Subsalicylate—Infection—Capecitabine—esophageal cancer	0.000309	0.00396	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—esophageal cancer	0.000308	0.00394	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—esophageal cancer	0.000303	0.00389	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Capecitabine—esophageal cancer	0.000296	0.00379	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Cisplatin—esophageal cancer	0.000288	0.0037	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—esophageal cancer	0.000283	0.00363	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—esophageal cancer	0.000277	0.00356	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Capecitabine—esophageal cancer	0.000273	0.0035	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Capecitabine—esophageal cancer	0.00027	0.00346	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Cisplatin—esophageal cancer	0.000268	0.00343	CcSEcCtD
Bismuth Subsalicylate—Rash—Cisplatin—esophageal cancer	0.000266	0.00341	CcSEcCtD
Bismuth Subsalicylate—Pain—Capecitabine—esophageal cancer	0.000266	0.0034	CcSEcCtD
Bismuth Subsalicylate—Constipation—Capecitabine—esophageal cancer	0.000266	0.0034	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Cisplatin—esophageal cancer	0.000265	0.0034	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Capecitabine—esophageal cancer	0.000256	0.00328	CcSEcCtD
Bismuth Subsalicylate—Nausea—Cisplatin—esophageal cancer	0.00025	0.00321	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Capecitabine—esophageal cancer	0.000247	0.00316	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Capecitabine—esophageal cancer	0.000246	0.00315	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—esophageal cancer	0.000233	0.00299	CcSEcCtD
Bismuth Subsalicylate—Infection—Methotrexate—esophageal cancer	0.00023	0.00294	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—esophageal cancer	0.00022	0.00282	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Capecitabine—esophageal cancer	0.00022	0.00282	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Capecitabine—esophageal cancer	0.000212	0.00272	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Methotrexate—esophageal cancer	0.000206	0.00263	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Capecitabine—esophageal cancer	0.000205	0.00263	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—esophageal cancer	0.000204	0.00261	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—esophageal cancer	0.000201	0.00258	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—esophageal cancer	0.000198	0.00253	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Capecitabine—esophageal cancer	0.000197	0.00253	CcSEcCtD
Bismuth Subsalicylate—Rash—Capecitabine—esophageal cancer	0.000196	0.00251	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Capecitabine—esophageal cancer	0.000196	0.00251	CcSEcCtD
Bismuth Subsalicylate—Headache—Capecitabine—esophageal cancer	0.000195	0.00249	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—esophageal cancer	0.000191	0.00244	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTT1—esophageal cancer	0.00019	0.00223	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000189	0.00222	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP2A6—esophageal cancer	0.000188	0.0022	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000187	0.0022	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000187	0.0022	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Capecitabine—esophageal cancer	0.000184	0.00236	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Methotrexate—esophageal cancer	0.000184	0.00235	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000183	0.00215	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—esophageal cancer	0.000183	0.00234	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—SOD2—esophageal cancer	0.000168	0.00197	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000167	0.00196	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000165	0.00194	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Methotrexate—esophageal cancer	0.000164	0.0021	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00016	0.00188	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—esophageal cancer	0.000158	0.00203	CcSEcCtD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000156	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Methotrexate—esophageal cancer	0.000153	0.00196	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP1B1—esophageal cancer	0.000151	0.00178	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Methotrexate—esophageal cancer	0.000147	0.00188	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PFN1—esophageal cancer	0.000147	0.00172	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CAPZA1—esophageal cancer	0.000146	0.00172	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000146	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Methotrexate—esophageal cancer	0.000146	0.00187	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—esophageal cancer	0.000146	0.00187	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—esophageal cancer	0.000145	0.00186	CcSEcCtD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000143	0.00168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP19A1—esophageal cancer	0.000142	0.00167	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NOS2—esophageal cancer	0.000138	0.00162	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Methotrexate—esophageal cancer	0.000137	0.00176	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000136	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000133	0.00157	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000129	0.00152	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000127	0.0015	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—CREBBP—esophageal cancer	0.000124	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000121	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.000119	0.0014	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000117	0.00138	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000116	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000116	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000116	0.00136	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000115	0.00135	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000113	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.000112	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NOS3—esophageal cancer	0.000111	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000111	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.00011	0.00129	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000107	0.00126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000105	0.00123	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000103	0.00121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000101	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	9.94e-05	0.00117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	9.85e-05	0.00116	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ATP1B2—esophageal cancer	9.67e-05	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	9.39e-05	0.0011	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	9.37e-05	0.0011	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	9.12e-05	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	9.09e-05	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	9.09e-05	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	8.91e-05	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	8.9e-05	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—DOCK2—esophageal cancer	8.75e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	8.67e-05	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.6e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.6e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—EP300—esophageal cancer	8.43e-05	0.000991	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	8.39e-05	0.000986	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	8.37e-05	0.000984	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	7.98e-05	0.000938	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	7.94e-05	0.000933	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.82e-05	0.000919	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—BLVRB—esophageal cancer	7.64e-05	0.000898	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC52A3—esophageal cancer	7.64e-05	0.000898	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—AQP3—esophageal cancer	7.57e-05	0.00089	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PFN1—esophageal cancer	7.55e-05	0.000888	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—esophageal cancer	7.48e-05	0.000879	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	7.26e-05	0.000853	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ATP4A—esophageal cancer	7.26e-05	0.000853	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SLC52A3—esophageal cancer	7.24e-05	0.000851	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	6.96e-05	0.000818	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KMT2D—esophageal cancer	6.91e-05	0.000812	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.82e-05	0.000802	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	6.61e-05	0.000777	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA1—esophageal cancer	6.49e-05	0.000763	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC10A2—esophageal cancer	6.49e-05	0.000763	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	6.33e-05	0.000744	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—esophageal cancer	6.23e-05	0.000733	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CFL1—esophageal cancer	6.12e-05	0.000719	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.1e-05	0.000717	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.07e-05	0.000714	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—BLVRB—esophageal cancer	6.06e-05	0.000713	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC52A3—esophageal cancer	6.06e-05	0.000713	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—esophageal cancer	6.03e-05	0.000709	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA2—esophageal cancer	5.94e-05	0.000698	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.81e-05	0.000682	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—GNG7—esophageal cancer	5.77e-05	0.000678	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—esophageal cancer	5.6e-05	0.000659	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PLCE1—esophageal cancer	5.52e-05	0.000649	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ADH7—esophageal cancer	5.52e-05	0.000649	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	5.52e-05	0.000649	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCC2—esophageal cancer	5.5e-05	0.000647	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.46e-05	0.000642	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.42e-05	0.000637	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FKBP1A—esophageal cancer	5.36e-05	0.00063	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	5.3e-05	0.000623	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.24e-05	0.000616	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—WIF1—esophageal cancer	5.23e-05	0.000615	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—DOCK2—esophageal cancer	5.23e-05	0.000615	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	5.18e-05	0.000609	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC10A2—esophageal cancer	5.16e-05	0.000606	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA1—esophageal cancer	5.16e-05	0.000606	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.09e-05	0.000598	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.99e-05	0.000587	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC52A3—esophageal cancer	4.91e-05	0.000577	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—BLVRB—esophageal cancer	4.91e-05	0.000577	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ADH1B—esophageal cancer	4.84e-05	0.000569	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CSNK1A1—esophageal cancer	4.83e-05	0.000568	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA2—esophageal cancer	4.72e-05	0.000554	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HSPA5—esophageal cancer	4.7e-05	0.000553	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMP—esophageal cancer	4.63e-05	0.000544	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.61e-05	0.000542	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP26A1—esophageal cancer	4.5e-05	0.000529	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.49e-05	0.000528	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALOX15—esophageal cancer	4.39e-05	0.000516	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.39e-05	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ADH7—esophageal cancer	4.38e-05	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PLCE1—esophageal cancer	4.38e-05	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.35e-05	0.000512	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.35e-05	0.000511	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.33e-05	0.000509	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTO1—esophageal cancer	4.19e-05	0.000492	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TPI1—esophageal cancer	4.19e-05	0.000492	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA1—esophageal cancer	4.17e-05	0.00049	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC10A2—esophageal cancer	4.17e-05	0.00049	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.14e-05	0.000486	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ELMO1—esophageal cancer	4.06e-05	0.000477	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALDOB—esophageal cancer	4.01e-05	0.000472	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GSTO1—esophageal cancer	3.97e-05	0.000466	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TPI1—esophageal cancer	3.97e-05	0.000466	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GAPDH—esophageal cancer	3.86e-05	0.000454	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ADH1B—esophageal cancer	3.84e-05	0.000452	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CRABP1—esophageal cancer	3.83e-05	0.00045	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA2—esophageal cancer	3.82e-05	0.000448	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ALDOB—esophageal cancer	3.8e-05	0.000447	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.73e-05	0.000438	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMP—esophageal cancer	3.67e-05	0.000432	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HIST1H2BM—esophageal cancer	3.66e-05	0.00043	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GAPDH—esophageal cancer	3.66e-05	0.00043	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GNG7—esophageal cancer	3.64e-05	0.000428	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.61e-05	0.000424	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.57e-05	0.00042	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PLCE1—esophageal cancer	3.55e-05	0.000417	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ADH7—esophageal cancer	3.55e-05	0.000417	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.53e-05	0.000415	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.51e-05	0.000412	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALOX15—esophageal cancer	3.48e-05	0.000409	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ABL1—esophageal cancer	3.48e-05	0.000409	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALDH2—esophageal cancer	3.41e-05	0.000401	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTO1—esophageal cancer	3.32e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TPI1—esophageal cancer	3.32e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTT1—esophageal cancer	3.25e-05	0.000381	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—XIAP—esophageal cancer	3.23e-05	0.00038	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP2A6—esophageal cancer	3.21e-05	0.000377	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.2e-05	0.000376	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALDOB—esophageal cancer	3.19e-05	0.000374	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ADH1B—esophageal cancer	3.11e-05	0.000366	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GAPDH—esophageal cancer	3.07e-05	0.00036	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.06e-05	0.00036	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.04e-05	0.000358	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ENO1—esophageal cancer	3.04e-05	0.000357	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CRABP1—esophageal cancer	3.04e-05	0.000357	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—B2M—esophageal cancer	3.01e-05	0.000353	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PSME1—esophageal cancer	3e-05	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PSME2—esophageal cancer	3e-05	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMP—esophageal cancer	2.97e-05	0.000349	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.96e-05	0.000348	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	2.92e-05	0.000343	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP26A1—esophageal cancer	2.89e-05	0.00034	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GNG7—esophageal cancer	2.89e-05	0.00034	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ENO1—esophageal cancer	2.88e-05	0.000339	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PSME2—esophageal cancer	2.84e-05	0.000334	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PSME1—esophageal cancer	2.84e-05	0.000334	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ALOX15—esophageal cancer	2.82e-05	0.000331	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CALR—esophageal cancer	2.73e-05	0.00032	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALDH2—esophageal cancer	2.71e-05	0.000318	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TPI1—esophageal cancer	2.69e-05	0.000316	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTO1—esophageal cancer	2.69e-05	0.000316	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FBXW7—esophageal cancer	2.64e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.62e-05	0.000308	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP1B1—esophageal cancer	2.59e-05	0.000304	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ALDOB—esophageal cancer	2.58e-05	0.000303	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTT1—esophageal cancer	2.58e-05	0.000303	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.55e-05	0.000299	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.54e-05	0.000298	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NOS2—esophageal cancer	2.51e-05	0.000295	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GAPDH—esophageal cancer	2.48e-05	0.000292	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CRABP1—esophageal cancer	2.46e-05	0.000289	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP19A1—esophageal cancer	2.43e-05	0.000286	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTGS1—esophageal cancer	2.41e-05	0.000284	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ENO1—esophageal cancer	2.41e-05	0.000284	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PSME2—esophageal cancer	2.38e-05	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PSME1—esophageal cancer	2.38e-05	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GNG7—esophageal cancer	2.34e-05	0.000275	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CREBBP—esophageal cancer	2.25e-05	0.000265	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HMOX1—esophageal cancer	2.22e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	2.2e-05	0.000259	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ALDH2—esophageal cancer	2.19e-05	0.000258	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.18e-05	0.000256	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFBR2—esophageal cancer	2.13e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCB1—esophageal cancer	2.13e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTT1—esophageal cancer	2.08e-05	0.000245	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP2A6—esophageal cancer	2.06e-05	0.000242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.05e-05	0.000241	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.05e-05	0.000241	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SMAD4—esophageal cancer	2.02e-05	0.000237	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NOS3—esophageal cancer	2.02e-05	0.000237	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS1—esophageal cancer	1.95e-05	0.00023	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ENO1—esophageal cancer	1.95e-05	0.00023	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.95e-05	0.000229	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.93e-05	0.000227	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PSME2—esophageal cancer	1.92e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PSME1—esophageal cancer	1.92e-05	0.000226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HMOX1—esophageal cancer	1.76e-05	0.000207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.73e-05	0.000203	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCB1—esophageal cancer	1.69e-05	0.000199	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.68e-05	0.000198	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP1B1—esophageal cancer	1.66e-05	0.000195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HIF1A—esophageal cancer	1.65e-05	0.000194	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.61e-05	0.000189	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP19A1—esophageal cancer	1.56e-05	0.000184	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EP300—esophageal cancer	1.54e-05	0.00018	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOS2—esophageal cancer	1.5e-05	0.000177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOTCH1—esophageal cancer	1.49e-05	0.000175	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HMOX1—esophageal cancer	1.42e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CREBBP—esophageal cancer	1.42e-05	0.000167	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.4e-05	0.000164	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCB1—esophageal cancer	1.37e-05	0.000161	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CREBBP—esophageal cancer	1.35e-05	0.000159	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.28e-05	0.00015	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NOS3—esophageal cancer	1.27e-05	0.00015	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOS3—esophageal cancer	1.21e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—esophageal cancer	1.17e-05	0.000137	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—esophageal cancer	1.14e-05	0.000134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CREBBP—esophageal cancer	1.13e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB2—esophageal cancer	1.13e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—esophageal cancer	1.1e-05	0.000129	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.03e-05	0.000122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NOS3—esophageal cancer	1.01e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—EP300—esophageal cancer	9.69e-06	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—esophageal cancer	9.66e-06	0.000113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EP300—esophageal cancer	9.19e-06	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CREBBP—esophageal cancer	9.14e-06	0.000107	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NOS3—esophageal cancer	8.18e-06	9.62e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—esophageal cancer	8.01e-06	9.41e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—esophageal cancer	7.83e-06	9.2e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EP300—esophageal cancer	7.69e-06	9.04e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—esophageal cancer	7.48e-06	8.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—esophageal cancer	7.17e-06	8.43e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—esophageal cancer	6.8e-06	7.99e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EP300—esophageal cancer	6.22e-06	7.32e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.69e-06	6.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—esophageal cancer	4.6e-06	5.41e-05	CbGpPWpGaD
